Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C102877
http://purl.obolibrary.org/obo/NCIT_C102877
|
|---|---|
| Preferred Name | Olinvacimab |
| Definitions |
A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. |
|---|---|
| prefLabel | Olinvacimab
|
| label | Olinvacimab
|
| PDQ_Closed_Trial_Search_ID | 738495
|
| code | C102877
|
| prefixIRI | NCIT:C102877
|
| in_subset | |
| Preferred_Name | Olinvacimab
|
| FDA_UNII_Code | VFH55IZ5VI
|
| Contributing_Source | FDA
|
| Maps_To |
Tanibirumab
Olinvacimab
|
| CAS_Registry | 2095504-49-5
|
| NCI_Drug_Dictionary_ID | 738495
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 738495
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C3490677
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |